Laekna Gets FDA Approval for Phase III Protocol of LAE002 Plus LAE001 in Prostate Cancer
Details : LAE002 (afuresertib, an AKT inhibitor) plus LAE001 (CYP17A1/CYP11B2 inhibitor) is being developed in patients with mCRPC following standard of care (SOC) treatment.
Product Name : LAE001
Product Type : Small molecule
Upfront Cash : Not Applicable
May 23, 2024
Lead Product(s) : LAE001
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Laekna Therapeutics Will Present Two Clinical Study Results in ESMO 2021
Details : It is a novel, potent, non-steroidal, reversible dual inhibitor of CYP17 and CYP11B2 (aldosterone synthase) that blocks both androgen and aldosterone synthesis, Therefore, unlike abiraterone acetate, LAE001 does not need a co-medication of prednisone.
Product Name : LAE001
Product Type : Small molecule
Upfront Cash : Not Applicable
July 26, 2021
Lead Product(s) : LAE001
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Reset All
